AJMC®: How is COPD definitively diagnosed in clinical practice, and how does this disease create a clinical burden on patients and caregivers? Dr Rali: COPD diagnosis requires both clinical context ...

Join Rich Jones and Dr Mitchell Rothstein as they talk advances in COPD treatment. FREE lunch from Carrabba’s Italian Grill ...

Editor’s note: This is an automatically generated transcript, which has been slightly edited for clarity. Please notify [email protected] if there are concerns regarding accuracy of the transcription.

Woman’s World has affiliate partnerships. We receive compensation when you click on a link and make a purchase. Learn more! Sure, having a cold or respiratory infection can temporarily make it harder ...

Growth is driven by rising COPD cases due to smoking and pollution, and enhanced therapeutic options like bronchodilators and biologics. Significant investments are improving diagnosis and treatment.

The BOREAS Phase III trial showed DUPIXENT reduced exacerbations by 30% and improved lung function by 160 mL at 52 weeks. Approximately 44 million COPD cases were recorded in 2023 in the 7MM, expected ...

AJMC®: What recent developments in the therapeutic landscape of chronic obstructive pulmonary disease (COPD) do you think have the greatest potential to shift how treatment is managed? Dr Martinez: ...

The FDA approved Ohtuvayre (ensifentrine) as a maintenance therapy for COPD (chronic obstructive pulmonary disease). The medication works as both a bronchodilator and an anti-inflammatory to ease ...

CHICAGO, July 8, 2025 /PRNewswire/ -- The American Lung Association is launching a new campaign to support and empower individuals living with chronic obstructive pulmonary disease (COPD) in rural and ...

The pulmonary emphysema market is poised for steady growth driven by rising COPD prevalence, an aging global population, and greater diagnostic awareness. Advances in inhaled therapies, targeted ...

Angiotensin-converting enzyme (ACE) inhibitor therapy may reduce all-cause mortality in idiopathic pulmonary fibrosis (IPF) but not in COPD.